Código QR (código de barras bidimensional)

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma

Abstract Background HER2-targeted therapies have revolutionized the treatment of HER2-positive breast cancer patients, leading to significant improvements in tumor response rates and survival. However, resistance and incomplete response remain considerable challenges. Proprotein convertase subtilisi...

ver descrição completa

Na minha lista:
Principais autores: Laura Scalambra, Francesca Ruzzi, Olga Maria Pittino, Maria Sofia Semprini, Chiara Cappello, Stefania Angelicola, Arianna Palladini, Patrizia Nanni, Louise Goksøyr, Cyrielle Fougeroux, Manuel L. Penichet, Adam Frederik Sander, Pier-Luigi Lollini
Formato: Artigo
Idioma:Inglês
Publicado em: BMC 2025-01-01
coleção:Journal of Translational Medicine
Assuntos:
Breast cancer
HER2
Therapy resistance
Cancer progression
PCSK9
Therapeutic cancer vaccines
Acesso em linha:https://doi.org/10.1186/s12967-025-06126-w
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados